Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
February 03 2020 - 7:30AM
Enochian Biosciences, a company focused on gene-modified cellular
therapy in infectious diseases and cancer, announces that it has
finalized the acquisition of a novel Hepatitis B Virus (HBV)
potential treatment or cure from Seraph Research Institute.
The preliminary, promising scientific data were
presented at the biannual HEP DART meeting last December, where it
was recognized as one of the best new therapies/novel strategies at
the conference. Jon Cohen of Science magazine tweeted
“Intriguing novel mechanism for attacking Hepatitis B virus.”
https://twitter.com/sciencecohen/status/1204891529275269120
Dr. Carol L. Brosgart, a recent addition to the
Enochian Board of Directors said, "I began my medical and research
career in the field of public health in the late 70’s, prior to the
development of clinical laboratory tests for Hepatitis B and the
Hepatitis B vaccine. At that time, there were no therapies for
Hepatitis B. Since that time, I have overseen the development and
licensure of several major therapies for the treatment of Hepatitis
B and HIV. With recent advances in our ability to cure
Hepatitis C, there is a new focus on finding curative regimens for
both Hepatitis B and HIV. I am very excited by this innovative
approach and its potential to become an effective treatment or cure
for Hepatitis B."
On November 25, Enochian announced it was
expanding its infectious diseases pipeline by entering into an
agreement in principle to acquire the exclusive license from
SRI.
Forward Looking Statement
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” plans,” “expects,”
“aims,” “intends” or similar expressions. Actual events or results
may differ materially from those projected in any of such
statements due to various uncertainties, including as set forth in
Enochian’s most recent Annual Report on Form 10-K filed with the
SEC. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement and Enochian undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024